$ACHFF News

Last published 5d ago

5d agoACHFFArch Biopartners Arranges Non-Brokered Private PlacementGlobeNewswireTORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today that it has arranged a non-brokered private placement offering of
2mo agoACHFFArch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT PeptideGlobeNewswireTORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSXV:ARCH, OTCQB:ACHFF) today announced that it has received central Institutional Review Board ("IRB") approval of the protocol and related
3mo agoACHFFArch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United StatesGlobeNewswireTORONTO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSXV:ARCH, OTCQB:ACHFF) today announced that the Company will expand its ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated
3mo agoACHFFArch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease ProgramGlobeNewswireTORONTO, July 17, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSXV:ARCH, OTCQB:ACHFF) today announced that it has engaged a U.S.-based laboratory specializing in bioengineering to accelerate the Company’s pre-IND
4mo agoACHFF SPROAvacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of DirectorsGlobeNewswireLONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated
5mo agoACHFFArch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New OrleansGlobeNewswireTORONTO, June 04, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSXV:ARCH, OTCQB:ACHFF) announced today that the Company will be featured in the 2026 American Diabetes Association Thought Leadership Series at their
5mo agoACHFFArch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trialGlobeNewswireTORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company's
6mo agoACHFFRoyal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKIGlobeNewswireTORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today that Royal Columbian Hospital (RCH) has begun patient recruitment in the Company's
7mo agoACHFFArch Biopartners Closes Non-Brokered Private PlacementGlobeNewswireTORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 common shares
7mo agoACHFFArch Biopartners Arranges Non-Brokered Private PlacementGlobeNewswireTORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today it has arranged a non-brokered private placement offering of 1,000,000 common shares
7mo agoACHFFArch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI TrialGlobeNewswireTORONTO, March 24, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today that the Fraser Health Authority has entered into a Clinical Trial Agreement ("CTA")
9mo agoACHFFArch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney DiseaseGlobeNewswireTORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) today announced that a scientific team led by Dr. Justin Chun at the University of Calgary has
9mo agoACHFFArch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the BoardGlobeNewswireTORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the Company's Board of Directors,
11mo agoACHFFArch Biopartners Announces Ethics Approval for St. Michael's Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT PeptideGlobeNewswireTORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today that the University Health Network Research Ethics Board ("UHN REB") has granted
11mo agoACHFFArch Biopartners Closes Non-Brokered Private PlacementGlobeNewswireTORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today it has closed a non-brokered private placement offering of 576,923 common shares
1y agoACHFFArch Biopartners Arranges Non-Brokered Private PlacementGlobeNewswireTORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today it has arranged a non-brokered private placement offering of 480,769 common shares
1y agoACHFFArch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British ColumbiaGlobeNewswireTORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today that the Fraser Health Research Ethics Board ("REB") has granted approval for the
1y agoACHFFArch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)GlobeNewswireArch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated in CKD,
1y agoACHFFArch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney InjuryGlobeNewswireFirst patient successfully completes dosing at Toronto General HospitalSt. Michael's Hospital is expected to be the next Canadian clinical site activatedArch is looking for additional clinical sites in North America to
1y agoACHFFArch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)GlobeNewswireTORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today that the investigator-led Phase II trial titled "Prevention Of NephroToxin Induced
1y agoACHFFArch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)GlobeNewswireTORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that the University Health Network (UHN) Research Ethics Board has granted approval
2y agoACHFFArch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug ToxinsGlobeNewswireArch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique off-target effects
2y agoACHFFArch Biopartners Announces GMP Manufacturing of Cilastatin Drug ProductGlobeNewswireTORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced that Dalton Pharma Services (Dalton) has completed the good manufacturing practice (GMP)
2y agoACHFFArch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)GlobeNewswireTORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that the University of Calgary's Conjoint Health Research Ethics Board (CHREB) has
2y agoACHFFSt. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney InjuryGlobeNewswireTORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that a research team from St. Michael's Hospital, a site of Unity Health Toronto,
2y agoACHFFUHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney InjuryGlobeNewswireTORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an academic research organization in
2y agoACHFFArch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney InjuryGlobeNewswireTORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for
2y agoACHFFArch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2GlobeNewswireBritish Medical Journal Open publishes paper detailing the results of the international Phase II human trial for LSALT peptide targeting acute lung and kidney inflammation in hospitalized patients infected with
2y agoACHFFUniversity of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney InjuryGlobeNewswireTORONTO, March 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that a research team from the University of Calgary's Cumming School of Medicine
2y agoACHFFArch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney InjuryGlobeNewswireTORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for
2y agoACHFFArch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney InjuryGlobeNewswireTORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that it had a pre-investigational new drug application (PIND) meeting with the U.S.
2y agoACHFFArch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney InjuryGlobeNewswireTORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that it has received a No Objection Letter from Health Canada to conduct a Phase II
2y agoACHFFArch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney InjuryGlobeNewswireTORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with
2y agoACHFFArch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT PeptideGlobeNewswireTORONTO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that it received approval in Turkey from the Kocaeli University Clinical Research
2y agoACHFFArch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT PeptideGlobeNewswireTORONTO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today it has submitted a Clinical Trial Application to Health Canada to obtain permission
3y agoACHFFArch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT PeptideGlobeNewswireTORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced that it has submitted applications to the Ministry of Health (MoH) and local Ethics
3y agoACHFFArch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury TrialGlobeNewswireApproval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to mediate organ inflammation
3y agoACHFFArch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT PeptideGlobeNewswireTORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ
3y agoACHFFArch Biopartners Receives Funding for Development of LSALT Peptide Drug ProgramGlobeNewswireTORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ
3y agoACHFFArch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney DiseaseGlobeNewswireTORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company focused on the development of innovative technologies and novel
4y agoACHFFArch Biopartners Adds Farris Smith as a Strategic AdvisorGlobeNewswireTORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammat
4y agoACHFFArch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical TrialsGlobeNewswireTORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. Da
4y agoACHFFCanadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)GlobeNewswireTORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch Biopartners", "Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced
4y agoACHFFArch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney InjuryGlobeNewswireTORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a
4y agoACHFFResearch Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)GlobeNewswireTORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch Biopartners", "Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced
4y agoACHFFArch Biopartners' Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) TrialGlobeNewswireLSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant type. LSALT is the first novel therapeutic to join the
5y agoACHFFArch Biopartners Provides Update on Phase II Trial for LSALT PeptideGlobeNewswireTORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that
5y agoACHFFArch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic DiseaseGlobeNewswireTORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that Arch sci
5y agoACHFFArch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ InflammationGlobeNewswireTORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has filed
5y agoACHFFArch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19GlobeNewswireTORONTO, May 04, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has complet